Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease

Journal of Pediatrics

Volumn 148, Issue 3, 2006, Pages 399-400

  Wada, Yasunori ^a   Kamei, Atsushi ^a   Fujii, Yukiharu ^a   Ishikawa, Ken ^a   Chida, Shoichi ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPICILLIN; IMMUNOGLOBULIN;

ANAMNESIS; APHAGIA; ARTICLE; BLOOD ANALYSIS; BRAIN ATROPHY; BRAIN INFARCTION; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL FEATURE; DRUG MEGADOSE; GAIT DISORDER; HEMIPLEGIA; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERREFLEXIA; LABORATORY TEST; MALE; MOTOR DYSFUNCTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT REFERRAL; PRESCHOOL CHILD; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION;

CEREBRAL INFARCTION; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 33646003214     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2005.10.027     Document Type: Article

References (12)

1. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Diagnosis, treatment, and long-term management of Kawasaki disease. a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114 (2004) 1708-1733
2. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33 (1991) 805-810
3. Zaidan R., Al Moallem M., Wani B.A., Shameena A.R., Al Tahan A.R., Daif A.K., et al. Thrombosis complicating high-dose intravenous immunoglobulin. report of three cases and review of the literature. Eur J Neurol 10 (2003) 367-372
4. Hefer D., and Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients. a case report and discussion of the relevant literature. Ann Hematol 83 (2004) 661-665
5. Terasawa K., Ichinose E., Matsuishi T., and Kato H. Neurological complications in Kawasaki disease. Brain Dev 5 (1983) 371-374
6. Suda K., Matsumura M., and Ohta S. Kawasaki disease complicated by cerebral infarction. Cardiol Young 13 (2003) 103-105
7. Reinhart W.H., and Berchtold P.E. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339 (1992) 662-664
8. Dalakas M.C. High-dose intravenous immunoglobulin and serum viscosity. risk of precipitating thromboembolic events. Neurology 44 (1994) 223-226
9. Wolberg A.S., Kon R.H., Monroe D.M., and Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 65 (2000) 30-34
10. Nishikawa M., Ichiyama T., Hasegawa M., Kawasaki K., Matsubara T., and Furukawa S. Safety from thromboembolism using intravenous immunoglobulin therapy in Kawasaki disease. study of whole-blood viscosity. Pediatr Int 45 (2003) 156-158
11. Ichiyama T., Nishikawa M., Hayashi T., Koga M., Tashiro N., and Furukawa S. Cerebral hypoperfusion during acute Kawasaki disease. Stroke 29 (1998) 1320-1321
12. Askalan R., Laughlin S., Mayank S., Chan A., MacGregor D., Andrew M., et al. Chickenpox and stroke in childhood. a study of frequency and causation. Stroke 32 (2001) 1257-1262